" class="no-js "lang="en-US"> Miles Congreve - Medtech Alert
Monday, April 15, 2024
Miles Congreve

Miles Congreve

About Miles Congreve

Miles is Chief Scientific Officer at Sosei Heptares, responsible for delivery of the company’s small molecule and peptide pre-clinical pipeline. Miles previously held senior medicinal chemistry positions at Astex and GSK. He is a recognized international expert in Structure-Based and Fragment-Based Drug Design (SBDD, FBDD). He has contributed to discovery of many agents studied in the clinic including Vofopitant, Lanabecestat, Onalespib, Capivasertib and Erdafitinib. He is co-inventor of Ribociclib (Kisqali®) which is FDA approved as first-line treatment for HR+/HER2- metastatic breast cancer. Miles has co-authored over 100 publications and is co-inventor of over 50 patents. His work in the area of FBDD has been highly influential, helping to establish and show the importance of the approach, including proposing the ‘Rule of 3’ for fragments. Miles was co-recipient of the Royal Society of Chemistry Malcolm Campbell Memorial Prize 2015 for his role in the seminal contributions to GPCR drug discovery made by Heptares. He is on the Editorial Advisory Board of the Journal of Medicinal Chemistry and Current Topics in Medicinal Chemistry. He teaches the principles of FBDD as a Faculty Member of the Drew Residential School on Medicinal Chemistry and Biology (ResMed, 2010-date).


Related Story

Sosei Heptares Receives Grant Funding from Wellcome to Advance the Development of Potent, Differentiated Oral Anti-Viral Small Molecules to Treat COVID-19

December 7 2021

Sosei Group Corporation (“the Company”; TSE: 4565) today announced it has received grant funding from […]

Sosei Heptares and InveniAI Enter a Multi-target AI-powered and GPCR-focused Drug Discovery Collaboration

July 6 2021

Sosei Group Corporation (“the Company”) (TSE: 4565), the world leader in GPCR-focused structure-based drug design and […]